BHPW
AVDL

Beverly Hills Private Wealth’s Avadel Pharmaceuticals AVDL Stock Holding History

Beverly Hills Private Wealth’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,379
Closed -$146K – 339
2024
Q2 		$146K Buy
+10,379
New +$169K 0.03% 342

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Beverly Hills Private Wealth's AVDL Position: Q3 2024 in Review

Beverly Hills Private Wealth sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 10,379 shares — an estimated $146K sold.

Beverly Hills Private Wealth first reported a position in AVDL in Q2 2024 and held it in 1 quarter. The position peaked at $146K in Q2 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • Beverly Hills Private Wealth reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Beverly Hills Private Wealth sold 10,379 Avadel Pharmaceuticals shares in Q3 2024, an estimated $146K.
  • Beverly Hills Private Wealth first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Beverly Hills Private Wealth's Avadel Pharmaceuticals position peaked at $146K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Beverly Hills Private Wealth's 13F filing for Q3 2024, filed 12 Nov 2024.